AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7733470
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 to 0.75 mg/kg)
Trial: 3349555
Drug: Edrophonium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.2 mg.kg‐1 (Group V)
Trial: 2644050
Drug: Edrophonium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.15 mg.kg‐1 (Group IV)
Trial: 2644050
Drug: Edrophonium 0.1
RxNorm normalized name: atropine-edrophonium 0.14 mg-10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.1 mg.kg‐1 (Group III)
Trial: 2644050
Drug: Edrophonium 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.05 mg.kg‐1 (Group II)
Trial: 2644050
Drug: Edrophonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1.0 mg.kg‐1 (Group I, controls)
Trial: 4911774
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 therapy
Trial: 11485076
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus compound (PA Co)
Trial: 2292635
Drug: Monthly Assertion
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly Assertion Training Boosters (ATB)
Trial: 2292635
Drug: Monthly Attention
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly Attention Placebo Boosters (APB)
Trial: 6108780
Drug: Metoprolol (ME)
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol (ME) 75 mg to 242 mg
Trial: 6108780
Drug: Pindolol (PI)
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol (PI) 7.5 mg to 23 mg
Trial: 6108780
Drug: Propranolol (PR)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (PR) 60 mg to 233 mg
Trial: 31655603
Drug: CHO-HG (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-HG (2.2 g CHO-HG·min-1)
Trial: 31721447
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine 2.4 mg/kg weekly
Trial: 24657236
Drug: Omalizumab 450
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab 450 mg
Trial: 24657236
Drug: Omalizumab 525
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab 525 mg
Trial: 24657236
Drug: Omalizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (all doses)
Trial: 20668329
Drug: In house
RxNorm normalized name: NIACINAMIDE 2 g in 100 mL TOPICAL CREAM [THE SKIN HOUSE Vital BrightCream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In house autologous platelet gel
Trial: 20668329
Drug: Vivostat‐ gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vivostat‐ gel
Trial: 18970976
Drug: BG00012 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG00012 240 mg three times daily
Trial: 15609386
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and aspirin
Trial: 9989124
Drug: Sertraline 50-100
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50-100 mg per day for 8 weeks
Trial: 1462277
Drug: Tenormin (atenolol)
RxNorm normalized name: atenolol Oral Tablet [Tenormin]
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenormin (atenolol) 100 mg daily
Trial: 3882061
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg three times a day for two weeks
Trial: 26561390
Drug: A/H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/H5N1 vaccine with AS03 adjuvant
Trial: 25060370
Drug: Clopidogrel (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (both doses)
Trial: 23249323
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of daytrip tickets and gift vouchers
Trial: 15723869
Drug: Standard periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard periodontal therapy (SPT)
Trial: 21757386
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal therapy (IPT)
Trial: 12049860
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg fondaparinux once daily
Trial: 12049860
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg enoxaparin twice daily
Trial: 9866433
Drug: Distant Healing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distant Healing (DH) treatment for 10 weeks
Trial: 7839424
Drug: Cross-match study
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-match study (CS) patients with detectable lymphocytotoxic antibodies (LA)
Trial: 2126584
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (100 mg/kg/day)
Trial: 2126584
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (30 mg/kg/day)
Trial: 28206788
Drug: Expectations for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectations for antibiotics (Experiment 1)
Trial: 28206788
Drug: Expectations for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectations for antibiotics (Experiment 2)
Trial: 26323830
Drug: Value-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Value-based cognitive-behavioural therapy (V-CBT) delivered within the first three months after a whiplash injury.
Trial: 19857076
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of jelly containing 0.3 g of S. euboea extract
Trial: 19857076
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (daily consumption of the same jelly without the enrichment)
Trial: 17156591
Drug: 1-hour pamidronate
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-hour pamidronate infusion
Trial: 17156591
Drug: 2-hour pamidronate
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-hour pamidronate infusion
Trial: 11694775
Drug: Continuous 24-hour
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 24-hour infusion of 5-fluorouracil (5-FU) 2,600 mg/m2 with folinic acid (FA) 500 mg/m2
Trial: 9366934
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (8.5 +/- 1.5 ml)
Trial: 9366934
Drug: Placebo (8.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8.3 +/- 1.8 ml)
Trial: 8904618
Drug: Fluconazole 50
RxNorm normalized name: fluconazole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 50 mg
Trial: 3111360
Drug: Ceftazidime 50
RxNorm normalized name: ceftazidime 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 50 mg/kg per dose administered intravenously every 8 h for 14 days
Trial: 3111360
Drug: Ceftazidime 75
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime 75 mg/kg per dose administered intravenously every 8 h for 14 days
Trial: 27733020
Drug: Topical oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxygen therapy
Trial: 24729102
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of alpha lipoic acid (ALA) supplementation daily for 8 weeks
Trial: 24729102
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules daily for 8 weeks
Trial: 21106264
Drug: IV N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV N-acetylcysteine plus high-dose hydration with normal saline
Trial: 21106264
Drug: High-dose hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hydration with normal saline
Trial: 18680998
Drug: Various intensive
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various intensive therapy schemes
Trial: 15768050
Drug: APC expression
RxNorm normalized name: APC-356433
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APC expression levels in leukocytes of relapse patients taking antipsychotic medication
Trial: 15768050
Drug: APC expression
RxNorm normalized name: APC-356433
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APC expression levels in leukocytes of first-episode drug-naïve patients
Trial: 12465429
Drug: Tacrolimus +
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus + MMF + Steroids (Tac/MMF/S)
Trial: 12465429
Drug: Tacrolimus +
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus + Azathioprine + Steroids (Tac/Aza/S)
Trial: 10502909
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (1 mg.kg‐1.hr‐1)
Trial: 8746887
Drug: Difference in
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difference in median survival times between treatment groups
Trial: 1646250
Drug: Intranasal human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal human calcitonin (hCT) plus sodium glycocholate (SGC)
Trial: 1646250
Drug: Intramuscular human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular human calcitonin (hCT) 100 U on alternate days
Trial: 1646250
Drug: Intranasal human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal human calcitonin (hCT) 100 U/day
Trial: 1646250
Drug: Intramuscular human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular human calcitonin (hCT) 100 U/day
Trial: 30633057
Drug: Pulsed flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed flow oxygen (2 to 10 L/min for volunteers; 1 to 5 L/min for patients)
Trial: 30633057
Drug: Continuous flow
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous flow oxygen (2 to 10 L/min for volunteers; 1 to 5 L/min for patients)
Trial: 30633057
Drug: Pulsed flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed flow oxygen (1 to 5 L/min for patients)
Trial: 30272234
Drug: Oral E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2 with/without cyclic vaginal progesterone
Trial: 27397522
Drug: Pregabalin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (50 mg every other day)
Trial: 27397522
Drug: Doxepin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (10 mg per day)
Trial: 26431666
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine combined with doxycycline
Trial: 23537882
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise programme (12-week, twice-weekly)
Trial: 11822612
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medical acupuncture treatment using an average of 12-13 needles per treatment, with more than 85 different acupoints utilized.
Trial: 11822612
Drug: Adjunctive treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive treatments including heat (36%-67%) and cupping (16%-21%).
Trial: 7877115
Drug: Adrenomedullary system
RxNorm normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullary system activation measured by norepinephrine (NE) and normetanephrine excretion
Trial: 31696972
Drug: Low-intensity cognitive
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity cognitive behavioural therapy (LICBT)
Trial: 31696972
Drug: Pre-treatment variables
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment variables (unemployment, suicide risk, neglect, medication, previous or concurrent treatments, longer duration of difficulties, comorbidities)
Trial: 29380013
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg Q6M for 10 years
Trial: 29380013
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg Q6M for 7 years
Trial: 28664242
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2 once weekly for 4 weeks)
Trial: 24902673
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (63 patients, 12 sessions of 60 min/week for 3 months)
Trial: 23435876
Drug: 1,25-D3 (calcitriol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25-D3 (calcitriol) at 60 mcg/m2 every 21 days with cisplatin 75 mg/m2 and docetaxel 75 mg/m2
Trial: 23435876
Drug: CYP24A1 SNP
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP24A1 SNP rs2762939 (C > G)
Trial: 18458207
Drug: Eszopiclone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone (3 mg nightly for 8 weeks) + Escitalopram (10 mg for 10 weeks)
Trial: 14990264
Drug: Glycyl-glutamine-supplemented parenteral
RxNorm normalized name: glycyl-isolysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyl-glutamine-supplemented parenteral nutrition (20 g of glutamine)
Trial: 14990264
Drug: Standard glutamine-free
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard glutamine-free parenteral nutrition
Trial: 14990264
Drug: Glycyl-glutamine-supplemented parenteral
RxNorm normalized name: glycyl-isolysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyl-glutamine-supplemented parenteral nutrition
Trial: 11380464
Drug: 7‐3 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐3 plus high‐dose cytarabine (HIDAC‐3‐7) chemotherapy
Trial: 11380464
Drug: 7‐3 chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐3 chemotherapy (standard dose cytarabine and daunorubicin)
Trial: 11380464
Drug: 7‐3 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐3 plus etoposide (7‐3‐7) chemotherapy
Trial: 9052890
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil (calcium channel blocker)
Trial: 7639352
Drug: BN 52021
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN 52021 (120 mg)
Trial: 31451130
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine (4 mg/kg)
Trial: 10323118
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate (50 mg/kg)
Trial: 27568351
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight Sodium Hyaluronate (3%) plus saline solution (3 mL sodium chloride-NaCl-0.9%) using a nebulizer ampoule for nasal douche, administered twice a day for 30 days.
Trial: 27568351
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (6 mL sodium chloride-NaCl-0.9%) using a nebulizer ampoule for nasal douche, administered twice a day for 30 days.
Trial: 27568351
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received Levofloxacin (500 mg for 10 days) and Prednisone (50 mg for 8 days, 25 mg for 4 days, and 12.5 mg for 4 days).
Trial: 26258474
Drug: Intermittent Screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Screening and Treatment with artemether-lumefantrine (ISTp-AL)
Trial: 26258474
Drug: Intermittent Preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Preventive Treatment with sulfadoxine-pyrimethamine (IPTp-SP)
Trial: 21781652
Drug: Hydralazine 182
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine 182 mg/day for fast acetylators
Trial: 21781652
Drug: Hydralazine 83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine 83 mg/day for slow acetylators
Trial: 21781652
Drug: Hydralazine 182
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine 182 mg/day for cancer patients (fast acetylators)
Trial: 21781652
Drug: Hydralazine 83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine 83 mg/day for cancer patients (slow acetylators)
Trial: 19349894
Drug: Oral arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral arginine supplementation (36.2 g of l-arginine-HCl)
Trial: 19349894
Drug: Placebo (51.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (51.2 g alanine)
Trial: 12009347
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day) for 6 months
Trial: 9538966
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro administered 10 min preprandial
Trial: 9538966
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro administered 20 min postprandial
Trial: 9538966
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro administered preprandially with high-carbohydrate meals
Trial: 9538966
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro administered preprandially with solid high-fat meal
Trial: 7480971
Drug: Taurine administered
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine administered intravenously before and during anesthesia
Trial: 2964388
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion 5-fluorouracil (5-FU) or 5-fluorouracil-deoxyribose as single agents or in combination with other drugs
Trial: 1535215
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide
Trial: 29200982
Drug: Native whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native whey protein (2×20 g)
Trial: 29200982
Drug: WPC‐80 (2×20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPC‐80 (2×20 g)
Trial: 23059756
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of chondroitin 4&6 sulfate 1200 mg (CS 1200)
Trial: 23059756
Drug: Three daily
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400)
Trial: 17682008
Drug: GONB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + triamcinolone 40 mg
Trial: 14587650
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg)
Trial: 14587650
Drug: Metoprolol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (12.5 mg)
Trial: 8971296
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (160 mg/h)
Trial: 8004841
Drug: Bisoprolol 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 20 mg
Trial: 27473400
Drug: Monthly payment
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly payment disbursement
Trial: 27473400
Drug: Semi-monthly payment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-monthly payment disbursement
Trial: 27473400
Drug: All intervention
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All intervention arms (monthly and semi-monthly)
Trial: 20495474
Drug: On-site, nurse-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site, nurse-administered intervention
Trial: 9106905
Drug: m-CPP (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-CPP (0.08 mg/kg)